This site is intended for UK healthcare professionals
Medscape UK Univadis Logo
Medscape UK Univadis Logo
News

NICE: carfilzomib with lenalidomide and dexamethasone for multiple myeloma

NICE has issued an appraisal document which does not recommend carfilzomib with lenalidomide and dexamethasone for previously treated multiple myeloma in adults.

Clinical trials data suggest clinical evidence came from the ASPIRE trial of carfilzomib with lenalidomide and dexamethasone compared with lenalidomide and dexamethasone.

Carfilzomib with lenalidomide and dexamethasone was associated with higher median progression-free survival (PFS) compared with lenalidomide and dexamethasone from 16.6 months to 26.1 months (hazard ratio [HR] 0.659; 95% CI 0.553-0.784; P<0.0001) in the intention-to-treat population.

Carfilzomib with lenalidomide and dexamethasone increased median overall survival compared with lenalidomide and dexamethasone from 40.4 months to 48.3 months (HR 0.794; 95% CI 0.667-0.945; P=0.0045) in the intention-to-treat population.

However, NICE said it is unclear how long the treatment benefit would last for carfilzomib with lenalidomide and dexamethasone.

This led to uncertainty about the cost-effectiveness. The most likely cost-effectiveness estimate for the treatment was higher than what NICE normally considers a cost-effective use of NHS resources.

NICE said collecting more data is not likely to resolve the uncertainty, so carfilzomib with lenalidomide and dexamethasone will not be available for use within the Cancer Drugs Fund.

The draft decision is open to public comment until 5pm, Tuesday October 13, 2020.


References


YOU MAY ALSO LIKE